Trending GLP-1 Therapies Research Papers

Hot New Top

4 days ago • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Metabolic, hormone, and reproductive changes linked to GLP-1 receptor drugs in women with high male hormones and insulin resistanceMetabolic, hormonal, and reproductive effects of GLP-1 receptor agonizts in hyperandrogenic insulin-resistant women: a systematic review.

📖 Top 30% JournalSystematic Review

yesterday • The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry

How Drugs Acting on GLP-1 Receptors May Affect Thinking About FoodGLP-1 Receptor Agonist Effects on Food-Related Cognition: A Cognitive Neuroscience Framework.

🎖️ Top 10% JournalArticle

1 week ago • International journal of molecular sciences

Clinical Outcomes of GLP-1 Receptor Agonist Treatment in Cancer PatientsGLP-1 Receptor Agonist Therapy in Patients with Cancer: A Review of Clinical Outcomes.

📖 Top 20% JournalSystematic Review

1 week ago • Nutrients

Effects of GLP-1 Receptor Drugs on Thinking Skills in Adults at Risk for Alzheimer's DiseaseImpact of GLP-1 Receptor Agonists on Cognitive Performance in Adults at Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

🎖️ Top 10% JournalSystematic Review

3 days ago • Frontiers in endocrinology

Heart and kidney benefits of GLP-1 and dual GIP/GLP-1 receptor drugs beyond blood sugar controlBeyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review.

🎖️ Top 10% JournalArticle

3 days ago • Frontiers in pharmacology

Pregnancy and birth outcomes after using GLP-1 and combined GLP-1/GIP receptor drugs during different timesPregnancy and perinatal outcomes following exposure to GLP-1 and dual GLP-1/GIP receptor agonists: a time-window-stratified systematic review and meta-analysis.

📖 Top 20% JournalArticle

yesterday • Annals of human biology

How GLP-1 receptor drugs relate to the rise of obesity, inactivity, and loneliness from an evolutionary viewEvolutionary perspectives on GLP-1 receptor agonists and the modern obesity, sedentary behaviour, and loneliness epidemics.

📖 Top 50% JournalArticle

1 week ago • Nutrients

Changes in Bile Acid Processing and Nutrient-Triggered Hormone Responses After Two Types of Digestive Weight-Loss Surgery: RYGB Versus SADI-SChanges in Bile Acid Metabolism and Nutrient-Stimulated Hormone Responses After Malabsorptive Metabolic Surgery: RYGB Versus SADI-S.

🎖️ Top 10% JournalObservational Study

6 days ago • Frontiers in pharmacology

Molecular insights into how GLP-1 receptor drugs work in type 2 diabetes and obesityInsights from multi-omics on GLP-1 receptor agonists in type 2 diabetes and obesity.

📖 Top 20% JournalArticle

1 week ago • Medicine

Effectiveness and safety of GLP-1 drugs in people with fatty liver disease linked to metabolism problems and liver inflammationEfficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis.

📖 Top 50% JournalSystematic Review

4 days ago • Expert review of clinical pharmacology

Using Diabetes Drugs Targeting GLP-1 Receptors as Possible Treatment for Substance Use DisordersFrom metabolic therapy to addiction care: a clinical pharmacology roadmap for GLP-1 receptor agonists in substance use disorders.

📖 Top 20% JournalArticle

1 week ago • Antioxidants (Basel, Switzerland)

GLP-1’s role in controlling oxidative signals in metabolism and related diseasesGLP-1 as a Regulator of Oxidative Signalling in Metabolic Health and Disease.

🎖️ Top 10% JournalArticle

1 week ago • Pharmaceutics

Retatrutide as a Single Drug Activating Three Hormone Receptors: Design, Development, and Review of New Phase 3 ResultsRetatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.

📖 Top 20% JournalArticle

6 days ago • BMC cardiovascular disorders

Comparing heart-related side effect patterns of GLP-1 receptor drugs using FDA reportsComparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS database.

📖 Top 30% JournalComparative Study

yesterday • Diabetology international

How Depression Levels Relate to Different Mental Health Paths During GIP and GLP-1 Receptor Agonist TreatmentsBaseline depressive-symptom severity and divergent psychological trajectories during GIP and/or GLP-1 receptor agonist therapy: a prospective ecological momentary assessment study.

📖 Top 50% JournalArticle

yesterday • Journal of diabetes and metabolic disorders

Effectiveness and safety of semaglutide compared to placebo in adults with overweight or obesity without diabetesEfficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials.

📖 Top 50% JournalArticle

2 days ago • Kidney research and clinical practice

Effects of combining two diabetes medications on people with chronic kidney disease in real-world settingsEffect of combined sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonist therapy in patients with chronic kidney disease: a real-world analysis.

📖 Top 20% JournalArticle

yesterday • Journal of health care for the poor and underserved

Medicaid Coverage Rules and Real-World Challenges in Getting TirzepatideCoverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access.

📖 Top 30% JournalCase Reports

4 days ago • The lancet. Diabetes & endocrinology

Effectiveness and safety of oral orforglipron in Japanese people with obesityEfficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.

🥇 Top 1% JournalArticle

4 days ago • Exploratory research in clinical and social pharmacy

How pharmacists help people stick to GLP-1 weight loss medicines by managing side effectsThe pharmacist's role in enhancing adherence to GLP1 based anti-obesity medications through comprehensive side effect management.

📖 Top 50% JournalArticle

4 days ago • Frontiers in pharmacology

GLP-1 drugs and DPP-4 inhibitors linked to memory loss in older adults with type 2 diabetesExploring the impact of GLP-1 analogues and DPP-4 inhibitors on cognitive decline in elderly patients with type 2 diabetes: a competing risks analysis from a real-world cohort.

📖 Top 20% JournalArticle

1 week ago • International journal of molecular sciences

Targeting multiple pathways beyond single GLP-1 drugs for precise treatment and lasting change in childhood obesityPrecision Pharmacotherapy for Childhood Obesity: Molecular Targets Beyond Single GLP-1 Receptor Agonism and a Framework for Disease Modification.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Effectiveness, side effects, and treatment adherence of Semaglutide and Liraglutide in Omani patientsReal-World Effectiveness, Documented Adverse Events, and Treatment Adherence of Semaglutide and Liraglutide in Omani Patients: A Retrospective Observational Study.

📖 Top 20% JournalArticle

1 week ago • Pharmaceutics

Advances in How Anti-Obesity Drugs Work in the BodyProgress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Body Weight and Metabolism Changes During Semaglutide and Tirzepatide Treatment in People from Türkiye Over TimeBody Weight Changes and Exploratory Metabolic Outcomes During Semaglutide and Tirzepatide Treatment: A Real-World Longitudinal Cohort Study from Türkiye.

📖 Top 20% JournalArticle

1 week ago • Frontiers in pharmacology

What people in Saudi Arabia know, think, and do about using GLP-1 receptor agonist medicinesKnowledge, attitudes, and practices among users of GLP-1 receptor agonists in Saudi Arabia: a cross-sectional study.

📖 Top 20% JournalArticle

1 week ago • Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Use of Glucagon-like Peptide-1 Receptor Agonists and Risk of Lymphedema After Breast Cancer SurgeryGlucagon-like peptide-1 receptor agonist use and risk of postmastectomy lymphedema in breast cancer survivors: a multicenter real-world cohort study.

📖 Top 20% JournalMulticenter Study

1 week ago • Metabolites

Weight gain after stopping GLP-1 and GIP/GLP-1 hormone treatments: A systematic reviewWeight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review.

📖 Top 20% JournalArticle

3 days ago • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

GLP-1 receptor agonist treatment linked to heart health in patients with fatty liver diseaseAssociation of GLP-1 receptor agonist therapy with cardiovascular outcomes in patients with MASLD: A translational study.

🎖️ Top 10% JournalArticle

3 days ago • Molecular metabolism

Removing GIP receptors from excitatory brain cells does not stop GIP receptor blockers from speeding up weight loss caused by GLP-1Loss of GIPR in glutamatergic neurons does not impair acceleration of GLP-1-induced weight loss by GIPR antagonism.

🥉 Top 5% JournalArticle